Cat. No. 5870
Alternative Name: EMD121974
Biological ActivityPotent and selective inhibitor of integrins αvβ3 and αvβ5 (IC50 values are 4.1 and 70 nM, respectively). Exhibits ~10-fold selectivity over gpIIb/IIIa. Increases endothelial monolayer permeability. Also exhibits antiangiogenic activity.
(Modifications: Phe-4 = D-Phe, Val-5 = Me-Val, Cyclizedl)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Alghisi et al (2009) The integrin antagonist cilengitide activates αvβ3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS One 4 e4449. PMID: 19212436.
Monnier et al (2008) CYR61 and αvβ5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma. Cancer Res. 68 7323. PMID: 18794119.
If you know of a relevant reference for Cilengitide please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Cilengitide from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Cilengitide, supplier, Potent, selective, inhibitors, inhibits, integrin, αvβ3, αvβ5, alphavbeta3, alphavbeta5, Tocris Bioscience, Integrin Inhibitor products
Find multiple products by catalog number
New Products in this Area
DR5 (TRAIL receptor) agonist; induces apoptosisBOP
Dual α9β/1α4β1 integrin inhibitor; preferentially mobilizes HSCsATN 161
α5β1 integrin receptor antagonist
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.